
https://www.science.org/content/blog-post/finishing-and-starting
# Article Title (Month Year)

## 1. SUMMARY
This commentary reflects on the challenging year of 2004 for the pharmaceutical industry, which the author describes as significantly worse than 2003. The author notes that drugs like Celebrex and Crestor are "in trouble," anticipates potential launch delays or cancellations for Novartis's COX-2 inhibitor, and highlights the precarious position of AstraZeneca's statin amid emerging safety concerns. The commentary warns that Merck had already begun layoffs and speculates that Pfizer and AstraZeneca may follow suit if their compounds are pulled from the market. It recalls a prior downturn during the Clinton healthcare plan proposal era but urges resilience and encourages research scientists to pursue novel, "out-of-the-ordinary" ideas as a path toward recovery and innovation in a difficult climate.

## 2. HISTORY
The period following this January 2005 commentary saw the dramatic, real-world safety crises and regulatory actions align with the author's concerns:

- **COX-2 inhibitors**: In rapid succession, Merck withdrew Vioxx in September 2004 (pre-dating the article), and Pfizer faced intense scrutiny over Celebrex and Bextra. Bextra was withdrawn from the market in April 2005. Celebrex remained available, but its market share and perception were significantly impacted, and Novartis did indeed halt its own COX-2 program. These events collectively undermined the COX-2 class and fueled a cascade of lawsuits.

- **Crestor (rosuvastatin)**: The article's concerns about safety controversies persisted, but Crestor was not withdrawn. It remained on the market and eventually became a major revenue driver for AstraZeneca, competing with Lipitor (atorvastatin). While targeted by media and critics, it did not suffer the same fate as Baycol (cerivastatin), Bayer's statin that was withdrawn.

- **Pharmaceutical job market and restructuring**: Merck and Pfizer proceeded with substantial layoffs and restructuring, driven by patent cliffs, pipeline gaps, and the aftermath of safety scandals. This period cemented a trend of consolidation and job insecurity within big pharma R&D, reshaping the sector's employment landscape.

- **Regulatory and public policy shifts**: The fallout from Vioxx, COX-2 inhibitors, and other safety issues intensified scrutiny from the FDA. This led to reforms aimed at strengthening post-marketing surveillance, risk management (e.g., Risk Evaluation and Mitigation Strategies, or REMS), and heightened expectations for cardiovascular safety outcomes in drug development. Public trust in pharmaceutical companies and disclosure practices eroded, fostering a more cautious regulatory and prescribing environment.

- **R&D climate and innovation**: The commentary's call to pursue "odd ideas" aligns with later trends in biopharma fragmentation; many large companies narrowed their innovation focus, while smaller biotechs and startups increasingly drove novel target and platform discovery. This dynamic reinforced the rise of external innovation and partner-based R&D models as a complement to internal programs.

## 3. PREDICTIONS
If the article contains specific predictions or strongly signaled expectations, evaluate them here in bullet points. If there are no clear predictions, omit this section.
- **Novartis delaying or canceling its COX-2 launch**: Novartis did pause or abandon its COX-2 program after the market turmoil, validating the author's expectation.
- **Crestor facing trouble, with possible withdrawal unless AstraZeneca chose an aggressive stance against Lipitor**: Crestor encountered significant controversy but was not withdrawn and eventually became a leading statin, demonstrating that AstraZeneca successfully navigated the challenge.
- **Pfizer and AstraZeneca would need layoffs if their compounds were pulled**: Pfizer and AstraZeneca undertook major restructurings and job cuts around this period, though the impetus was broader than a single withdrawal.
- **A worsening hiring environment for pharmaceutical roles**: The sector experienced job cuts and hiring slowdowns as restructuring continued, aligning with the commentary.

## 4. INTEREST
Rating: **5/10**
The author provides a candid, contemporaneous industry perspective that captures the painful inflection point of 2004-2005. However, the commentary is constrained by its short-term, news-cycle nature and lacks deep analysis of underlying drivers (e.g., regulatory, reimbursement, and R&D productivity issues beyond safety scandals). It remains a period piece with limited broader scientific or policy implications beyond the era.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20050102-finishing-and-starting.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_